Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies

Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01782-19. doi: 10.1128/AAC.01782-19. Print 2019 Dec 20.
No abstract available

Keywords: Pseudomonas aeruginosa; ceftolozane-tazobactam; continuous venovenous hemodiafiltration; medical intensive care unit; molecular adsorbent recirculating system; off-label; pharmacokinetics.

Publication types

  • Letter

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Cephalosporins / pharmacokinetics*
  • Critical Illness*
  • Female
  • Hemodiafiltration / methods
  • Humans
  • Microbial Sensitivity Tests
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology
  • Pseudomonas Infections / drug therapy
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / pathogenicity

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • ceftolozane